Completed PHASE4 INTERVENTIONAL NCT00140062

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With Usual Care Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension

Sponsor: Pfizer

Conditions Glaucoma, Open-Angle Ocular Hypertension

Interventions latanoprost 0.005% (Xalatan)

Updated 6 times since 2017 Last updated: Apr 4, 2008 Started: Feb 28, 2002 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Glaucoma, Open-Angle and Ocular Hypertension, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2002. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ekenäs, Finland , Helsinki, Finland , JÃ¶nkÃ¶ping, Sweden , Karlstad, Sweden , Kristianstad, Sweden , Kuopio, Finland , Lahti, Finland , Linköping, Sweden , Ludvika, Sweden , Mölndal, Sweden and 13 more locations